Antimicrobial Resistance

Antimicrobial Resistance

In this article we will discuss Antimicrobial Resistance (AMR)

In this article, we will discuss Antimicrobial Resistance. So, let’s get started.

Antimicrobial Resistance (AMR)

  • Antimicrobial Resistance is the resistance acquired by any microorganism (bacteria, viruses, fungi, parasite, etc.) against antimicrobial drugs that are used to treat infections.
  • It occurs when a microorganism changes over time and no longer responds to medicines making infections harder to treat and increasing the risk of disease spread, severe illness and death.
  • The World Health Organisation (WHO) has identified AMR as one of the top ten threats to global health.
  • In India, over 56,000 newborn deaths each year due to sepsis caused by organisms that are resistant to first line antibiotics.
  • A study reported by ICMR (Indian Council of Medical Research) from 10 hospitals showed that when Covid patients acquire drug-resistant infections in hospitals, the mortality is almost 50-60%.
  • The multi-drug resistance determinant, New Delhi Metallo-beta-lactamase-1 (NDM-1), emerged from this region.
  • Africa, Europe and other parts of Asia have also been affected by multi-drug resistant typhoid originating from South Asia.

GRAM Report (AMR)

  • The Global Research on Antimicrobial Resistance (GRAM) report provides the most comprehensive estimate of the global impact of antibiotic resistance to date.
  • According to the report, 1.27 million people died in 2019 as a direct result of AMR (AntiMicrobial Resistance).
  • Lower respiratory infections accounted for more than 1.5 million deaths associated with resistance in 2019, making it the most burdensome infectious syndrome.
  • Amongst pathogens, E coli was responsible for the most deaths in 2019, followed by K pneumoniae, S aureus, A baumannii, S pneumoniae, and M tuberculosis.
  • As per the yearly trends reported by the ICMR, since 2015, India reports a high level of resistance in all these pathogens, especially E coli and K pneumoniae.

Concerns Regarding AMR

  • The growth of AMR has proved to be a major challenge in the treatment of sepsis, which is a life-threatening condition and, unfortunately, the failure of antibiotics is leading to deaths which are preventable.
  • AMR is also undermining and undoing medical advances made over decades, especially for high-burden diseases like tuberculosis and various cancers.
  • It is putting the gains of the Millennium Development Goals at risk and endangers achievement of the Sustainable Development Goals.
  • Untreated wastewater from medical facilities is awash with chemical compounds that promote superbugs.
  • The concoction of self-medication and over the counter (OTC) antibiotic availability has led to one of the highest rates of antibiotic resistance in the world.

Initiatives that have been taken by the Government to Prevent AMR

  • AMR Surveillance and Research Network (AMRSN) was launched in 2013, to generate evidence and capture trends and patterns of drug resistant infections in the country.
  • The National Action Plan on AMR focuses on One Health approach and was launched in April 2017 with the aim of involving various stakeholder ministries/departments.
  • ICMR along with Research Council of Norway (RCN) initiated a joint call for research in antimicrobial resistance in 2017.
  • ICMR along with the Federal Ministry of Education and Research (BMBF), Germany has a joint Indo-German collaboration for research on AMR.
  • ICMR has initiated Antibiotic Stewardship Program (AMSP) on a pilot project across India to control misuse and overuse of antibiotics in hospital wards and ICUs.

Challenges Related to Preventing AMR

  • Inadequate Information Systems: The resistance rates reported by the hospitals and laboratories do not automatically translate to disease burden unless each resistant isolate is correlated with the clinical outcomes in the patients from whom they were isolated.
  • This has to do with inadequate hospital information systems in most public sector funded healthcare facilities in India and many low-middle income countries.
  • Insufficient Fundings: No new classes of antibiotics have made it to the market in the last three decades, largely on account of inadequate incentives for their development and production.
  • Lack of an urgent action is leading towards an antibiotic apocalypse – a future with bacteria becoming completely resistant to treatment.
  • Exclusion of Antibiotic Residues: In India, current effluent standards do not include antibiotic residues, and thus they are not monitored in the pharmaceutical industry effluents.
  • Inefficiency of Schemes: The National Action Plan for AMR, approved in 2017, completes its official duration this year. The progress under the plan has been far from satisfactory.
  • Too many players, missing governance mechanisms and absence of funding are the key impediments to the effective rollout of the scheme.
  • Underreporting in GRAM Report: Only a fraction of the Indian data, available through the WHO-GLASS portal, has been included in the GRAM report.
  • India has been reporting high levels of resistance to fluoroquinolones, cephalosporins and carbapenems across the Gram-negative pathogens that cause almost 70% of infections in communities and hospitals.

By competitiveworld27

Competitive World is your online guide for competitive exam preparation

Leave a Reply

Your email address will not be published. Required fields are marked *